For Doctors in a Hurry
- Clinicians lack data on the prevalence of subclinical joint damage in patients with asymptomatic hyperuricemia.
- The researchers performed standardized ultrasound examinations on 269 participants with serum urate levels at or above 0.48 mmol/L.
- 38.7% of participants exhibited at least one definite double contour or tophus on ultrasound imaging.
- The study concludes that while gout features are common, the total burden of crystal deposition remains low.
- These findings suggest that asymptomatic hyperuricemia is associated with subclinical joint inflammation and structural damage in some patients.
The Hidden Burden of Subclinical Urate Deposition
Hyperuricemia is increasingly recognized not merely as a precursor to gouty arthritis, but as a systemic metabolic state linked to significant cardiovascular and renal comorbidities [1]. While traditional management guidelines often defer treatment until the first acute flare, emerging evidence suggests that monosodium urate crystals may deposit silently in joint tissues during a prolonged preclinical phase [2, 3]. These subclinical deposits are not benign, as they have been associated with an increased prevalence and severity of degenerative changes, such as knee osteoarthritis, even in patients who have never experienced inflammatory symptoms [4]. Consequently, identifying which patients harbor these occult lesions is a growing priority for clinicians seeking to prevent long term structural damage [5]. A new study now provides a detailed analysis of how standardized ultrasound scoring can detect these hidden urate deposits and their relationship to early joint inflammation.
Standardized Ultrasound Assessment of the Preclinical Phase
To better characterize the preclinical phase of gout, the researchers conducted a study of 269 participants with asymptomatic hyperuricemia, defined as having serum urate levels of 0.48 mmol/L or higher. This cohort was specifically selected to represent patients before the onset of clinical disease; all participants had no history of previous gout flares and no visible subcutaneous tophi (firm lumps of urate crystals under the skin). The primary objective was to describe the musculoskeletal ultrasound features of this population using the Outcome Measures in Rheumatology (OMERACT) gout semiquantitative scoring system, a standardized tool that allows clinicians to grade the severity of crystal deposition and joint damage. The study utilized a rigorous, standardized ultrasound protocol that involved the examination of multiple anatomical sites prone to urate deposition, including the bilateral patellar tendons, the knees, the first and second metatarsophalangeal joints (MTPs), and the Achilles tendons. During these scans, the researchers evaluated three specific types of urate-related lesions: the double contour sign (a hyperechoic band over the superficial margin of articular cartilage), tophi (circumscribed collections of crystals), and aggregates (small, bright reflections). Each of these features was scored using the OMERACT gout ultrasound semiquantitative scoring system on a scale of 0 to 3. Within this framework, a score of 0 represents the absence of the feature, while a score greater than 1 is required to indicate a definite finding of urate deposition. This threshold ensures that only clinically significant crystal presence is categorized as a positive result, providing a clear benchmark for identifying subclinical pathology in the absence of overt inflammatory symptoms.
Prevalence and Distribution of Occult Crystal Deposits
Systematic ultrasound evaluation of 269 asymptomatic individuals revealed that subclinical monosodium urate crystal deposition is common even in the absence of clinical gout. The researchers found that 38.7% of participants had at least 1 definite double contour and/or tophus on ultrasound, defined by a score of 2 or higher on the Outcome Measures in Rheumatology (OMERACT) scale. To quantify the total burden of crystal deposition, the study utilized a semiquantitative double contour-tophus (SQDT) sum score, which combined the individual scores for double contour (the hyperechoic layer of crystals on the cartilage surface) and tophi (discrete collections of urate) across all scanned sites. This SQDT sum score had a maximum possible value of 60, providing a comprehensive metric for total crystal load. Despite the high prevalence of detectable crystals, the overall volume of deposition remained relatively limited in this preclinical cohort. The median SQDT sum score was 2, with an interquartile range (IQR) of 0 to 4, indicating that while crystals are present, the amount of monosodium urate crystal deposition on ultrasound in this population is low compared to patients with established gouty arthritis. When analyzing the distribution of these findings, the researchers noted that double contour scores were the primary contributor to the total SQDT sum score. The second largest contributor to the total score was the presence of tophi at the first metatarsophalangeal joint (MTP), identifying this site as a critical area for early sonographic screening in patients with elevated serum urate.
Linking Silent Deposits to Active Joint Damage
The clinical significance of these occult deposits extends beyond their mere presence, as the researchers examined relationships between different ultrasound lesions to determine if crystal accumulation correlates with structural or inflammatory changes. In addition to identifying urate crystals, the scanned joints were evaluated for erosion (cortical breaking or bone loss), synovial hypertrophy (pathological thickening of the joint lining), and power Doppler activity, which serves as a marker for increased blood flow indicating active inflammation. The analysis revealed that double contour findings were associated with synovial hypertrophy at the first and second metatarsophalangeal joints, suggesting that the presence of a hyperechoic layer of crystals on the cartilage surface is linked to early proliferative changes in the synovium even before a patient experiences their first gout flare. The presence of tophi, or discrete collections of monosodium urate, was linked to more advanced markers of joint pathology. Specifically, tophus findings were associated with erosion at the first metatarsophalangeal joint, as well as synovial hypertrophy and power Doppler activity at the first metatarsophalangeal joint. These correlations indicate that even in the absence of clinical symptoms, the deposition of urate crystals is not a benign state. Instead, the findings demonstrate that ultrasound features of gout in asymptomatic hyperuricemia are associated with subclinical joint damage and inflammation, suggesting that the transition from hyperuricemia to gouty arthritis involves active pathological processes that occur well before the onset of acute pain.
References
1. Du L, Yao Z, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01916-y
2. Cruz D, Li-Yu J, Bayson RJ, Zamora L, Lichauco J. A Cross Sectional Validation Study of Sonographic Findings of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia. Philippine journal of internal medicine. 2023. doi:10.65564/pjim.e5edd6018c
3. Calvo-Aranda E, Nogal LB, Cáceres BBB, et al. Preclinical gout is common in the patient with stage 3-5 chronic kidney disease. Relevance of musculoskeletal ultrasound.. Nefrología. 2024. doi:10.1016/j.nefroe.2024.11.006
4. Howard RG, Samuels J, Gyftopoulos S, et al. Presence of gout is associated with increased prevalence and severity of knee osteoarthritis among older men: results of a pilot study.. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2015. doi:10.1097/RHU.0000000000000217
5. Sun M, Lyu Z, Wang C, et al. 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70375
